scholarly journals Leukaemic mantle cell lymphoma with t(11;14) and trisomy 12 showing clinical features of state A0 B cell chronic lymphocytic leukaemia

1995 ◽  
Vol 48 (3) ◽  
pp. M165-M166 ◽  
Author(s):  
J R Neilson ◽  
M Cai ◽  
N Bienz ◽  
M J Leyland
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
B Cell ◽  
Mantle Cell Lymphoma ◽  
Clinical Features ◽  
Lymphocytic Leukaemia ◽  
Cell Lymphoma ◽  
Cell Chronic Lymphocytic Leukaemia ◽  
Mantle Cell ◽  
Trisomy 12

Synchronous Mantle Cell Lymphoma, Chronic Lymphocytic Leukaemia and Melanoma in a Single Lymph Node

2010 ◽  
Vol 123 (3) ◽  
pp. 194-196 ◽  
Author(s):  
Juanah Addada ◽  
Parameswaran Anoop ◽  
John G. Swansbury ◽  
Andy Wotherspoon ◽  
J. Meirion Thomas ◽  
...  
Keyword(s):  
Lymph Node ◽  
Chronic Lymphocytic Leukaemia ◽  
Mantle Cell Lymphoma ◽  
Lymphocytic Leukaemia ◽  
Cell Lymphoma ◽  
Mantle Cell

the Utility of CD200 Expression In the Differentiation of Mantle Cell Lymphoma and B-Cell Chronic Lymphocytic Leukaemia: A Single Centre Experience.

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 1673-1673 ◽  
Author(s):  
Neha Bhatnagar ◽  
Faith Wright ◽  
Dimpna McAleese ◽  
Christopher J McNamara
Keyword(s):  
B Cell ◽  
Predictive Value ◽  
Lymphoproliferative Disorder ◽  
Lymphocytic Leukaemia ◽  
Cell Lymphoma ◽  
Lymphoproliferative Disorders ◽  
Single Centre ◽  
Neoplastic Cells ◽  
Cell Chronic Lymphocytic Leukaemia ◽  
Mantle Cell

Abstract Abstract 1673 Introduction: Mature B-cell lymphoproliferative disorders that present with a leukemic phase may have overlapping morphological and immunophenotypic features. Accurate diagnosis is essential to determine prognosis and therapy. B-cell chronic lymphocytic leukaemia (B-CLL) and mantle cell lymphoma (MCL) both express CD5 but usually have divergent clinical courses. Conventional markers are able to discriminate in many cases but a significant proportion of cases require more detailed analysis. CD200 is a membrane glycoprotein that has been reported to differentiate between B-CLL and MCL. It is expressed on resting and activated T and B cells, but not on NK cells, monocytes, granulocytes or platelets. We prospectively assessed the utility of this antibody in a single centre, servicing haematology units in North London. Methods: Over a 12 month period we prospectively assessed the expression of CD200 (Clone MRC OX-104, BD Pharmingen) on neoplastic cells of patients with presenting with mature B-cell lymphoproliferative disorders. EDTA anti-coagulated peripheral blood and bone marrow underwent a lyse/wash technique before being acquired on a BD FACS Canto II flow cytometer equipped with DIVA 6.1.2 software. A lymphoid gating strategy was used to analyse the data and expression of more than 20% of nucleated cells referenced to a negative internal control was considered positive. A diagnosis was made using all available data according to the WHO classification of haematopoietic tumours, including the 5 point CLL score. The predictive value of CD200 expression was subsequently assessed. Results: There were 100 patients (58M: 42F) with a median age of 70 years (range 29–92). CD200 was present on the neoplastic cells of all 78 patients with B-CLL; in all 7 MCL patients CD200 was negative; 15 patients had CD5 negative B-cell lymphoproliferative disorder with variable expression of CD200. The specificity of CD200 negativity in the setting of CD5 positive B-cell clone was 100% for MCL. The positive predictive value of CD200 for CLL was 97.5% with a sensitivity of 100% and a Pearson's correlation coefficient of 1. Conclusion: Our results confirm CD200 expression in the neoplastic cells of B-CLL patients but not in MCL. This antibody may contribute to the accurate differentiation between B-CLL and MCL in patients presenting with the diagnostic problem of a CD5- positive lymphoproliferative disorder. We propose to add CD200 to our diagnostic B-cell lymphoma panel. Further studies are needed to determine whether CD200 could replace other immunophenotypic strategies currently used in this situation, such as CD23, FMC7 and intensity of CD22/CD79b expression. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document